WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

WestHill Financial Advisors Inc. lowered its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 15.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 238,333 shares of the company's stock after selling 45,000 shares during the quarter. Nurix Therapeutics comprises approximately 1.2% of WestHill Financial Advisors Inc.'s holdings, making the stock its 16th largest holding. WestHill Financial Advisors Inc. owned 0.48% of Nurix Therapeutics worth $5,355,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock worth $95,000 after buying an additional 3,424 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Nurix Therapeutics in the first quarter valued at about $123,000. ProShare Advisors LLC lifted its position in Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock worth $176,000 after buying an additional 998 shares in the last quarter. Dark Forest Capital Management LP bought a new stake in Nurix Therapeutics during the 2nd quarter worth about $201,000. Finally, Caxton Associates LP acquired a new stake in Nurix Therapeutics in the 1st quarter valued at about $225,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They set an "outperform" rating and a $26.00 target price on the stock. Royal Bank of Canada cut their price target on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They issued a "buy" rating and a $41.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an "overweight" rating in a report on Monday, July 15th. Finally, Truist Financial started coverage on shares of Nurix Therapeutics in a research note on Wednesday, July 31st. They issued a "buy" rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.71.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.33 during trading hours on Friday, hitting $25.05. The company's stock had a trading volume of 859,356 shares, compared to its average volume of 897,639. The company has a market capitalization of $1.23 billion, a PE ratio of -8.58 and a beta of 2.22. The stock has a 50 day moving average of $23.73 and a 200 day moving average of $19.65. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $26.43.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The business had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 2,490 shares of the company's stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the transaction, the chief financial officer now directly owns 54,479 shares of the company's stock, valued at $1,126,080.93. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of the business's stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares of the company's stock, valued at $1,126,080.93. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Christine Ring sold 3,290 shares of the firm's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the transaction, the insider now owns 24,592 shares of the company's stock, valued at $614,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,105 shares of company stock worth $1,507,181 over the last ninety days. Company insiders own 7.20% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.